Understand the source comparison
Survodutide Compare to Other Research Peptides: Comparison Overview
The table below breaks down receptor targets, primary metabolic pathways, tissue-specific effects, and typical research applications across survodutide and commonly compared peptides. Survodutide GLP-1 + Glucagon Dual incretin/glucagon signaling. Appetite supp
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below breaks down receptor targets, primary metabolic pathways, tissue-specific effects, and typical research applications across survodutide and commonly compared peptides.
- Survodutide
- GLP-1 + Glucagon
- Dual incretin/glucagon signaling. Appetite suppression + direct lipolysis
- Direct fat oxidation via cAMP-PKA, 42.7% steatosis reduction in 48 weeks
- NAFLD/NASH studies, metabolic syndrome, body recomp with lean preservation
- Best for multi-pathway metabolic research requiring both fat loss and hepatic lipid clearance
- Semaglutide
- GLP-1 only
- Incretin-mediated insulin secretion + gastric emptying delay
- Indirect via weight loss and insulin sensitivity. Slower timeline
- Obesity, T2DM, cardiovascular outcomes, appetite regulation studies
- Gold standard for GLP-1 research. Well-characterized, extensive clinical data, single-pathway clarity
- Tirzepatide
- GLP-1 + GIP
- Dual incretin (GLP-1 and GIP). Enhanced insulin response
- Indirect via improved glycemic control. Similar to semaglutide
- Glycemic control, weight loss, incretin pathway interactions
- Superior weight loss vs GLP-1 alone but lacks direct hepatic lipid oxidation of survodutide
- GHRP-2
- Ghrelin (GHSR-1a)
- Growth hormone secretion via pituitary stimulation
- Minimal direct hepatic effects. GH/IGF-1 pathway
- Lean mass studies, anabolic signaling, sleep architecture, GH pulsatility
- Not comparable for fat loss. Targets anabolic processes, often paired with lipolytic peptides
- MK-677 (Ibutamoren)
- Ghrelin mimetic
- Sustained GH elevation without pituitary desensitization
- Minimal. Some indirect via IGF-1 insulin sensitivity
- Long-term GH studies, elderly populations, appetite stimulation
- Oral bioavailability advantage but mechanistically separate from glucagon or GLP-1 pathways